全文获取类型
收费全文 | 2099篇 |
免费 | 99篇 |
国内免费 | 82篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 127篇 |
妇产科学 | 27篇 |
基础医学 | 223篇 |
口腔科学 | 45篇 |
临床医学 | 280篇 |
内科学 | 571篇 |
皮肤病学 | 58篇 |
神经病学 | 70篇 |
特种医学 | 321篇 |
外科学 | 141篇 |
综合类 | 40篇 |
预防医学 | 64篇 |
眼科学 | 22篇 |
药学 | 117篇 |
肿瘤学 | 163篇 |
出版年
2023年 | 16篇 |
2022年 | 24篇 |
2021年 | 28篇 |
2020年 | 17篇 |
2019年 | 27篇 |
2018年 | 22篇 |
2017年 | 30篇 |
2016年 | 27篇 |
2015年 | 35篇 |
2014年 | 41篇 |
2013年 | 51篇 |
2012年 | 57篇 |
2011年 | 59篇 |
2010年 | 68篇 |
2009年 | 74篇 |
2008年 | 58篇 |
2007年 | 94篇 |
2006年 | 53篇 |
2005年 | 59篇 |
2004年 | 61篇 |
2003年 | 47篇 |
2002年 | 49篇 |
2001年 | 45篇 |
2000年 | 44篇 |
1999年 | 46篇 |
1998年 | 114篇 |
1997年 | 100篇 |
1996年 | 121篇 |
1995年 | 97篇 |
1994年 | 97篇 |
1993年 | 81篇 |
1992年 | 44篇 |
1991年 | 36篇 |
1990年 | 35篇 |
1989年 | 44篇 |
1988年 | 50篇 |
1987年 | 37篇 |
1986年 | 45篇 |
1985年 | 49篇 |
1984年 | 22篇 |
1983年 | 28篇 |
1982年 | 22篇 |
1981年 | 23篇 |
1980年 | 21篇 |
1978年 | 12篇 |
1977年 | 16篇 |
1976年 | 14篇 |
1975年 | 7篇 |
1966年 | 4篇 |
1965年 | 4篇 |
排序方式: 共有2280条查询结果,搜索用时 15 毫秒
81.
82.
Erik P A van Iperen Suthesh Sivapalaratnam S Matthijs Boekholdt G Kees Hovingh Stephanie Maiwald Michael W Tanck Nicole Soranzo Jonathan C Stephens Jennifer G Sambrook Marcel Levi Willem H Ouwehand John JP Kastelein Mieke D Trip Aeilko H Zwinderman 《European journal of human genetics : EJHG》2014,22(6):809-813
In recent years, multiple loci dispersed on the genome have been shown to be associated with coronary artery disease (CAD). We investigated whether these common genetic variants also hold value for CAD prediction in a large cohort of patients with familial hypercholesterolemia (FH). We genotyped a total of 41 single-nucleotide polymorphisms (SNPs) in 1701 FH patients, of whom 482 patients (28.3%) had at least one coronary event during an average follow up of 66 years. The association of each SNP with event-free survival time was calculated with a Cox proportional hazard model. In the cardiovascular disease risk factor adjusted analysis, the most significant SNP was rs1122608:G>T in the SMARCA4 gene near the LDL-receptor (LDLR) gene, with a hazard ratio for CAD risk of 0.74 (95% CI 0.49–0.99; P-value 0.021). However, none of the SNPs reached the Bonferroni threshold. Of all the known CAD loci analyzed, the SMARCA4 locus near the LDLR had the strongest negative association with CAD in this high-risk FH cohort. The effect is contrary to what was expected. None of the other loci showed association with CAD. 相似文献
83.
Katherine JP Schwenger Johane P Allard 《World journal of gastroenterology : WJG》2014,20(7):1712-1723
Non-alcoholic fatty liver disease(NAFLD)ranges from simple steatosis to nonalcoholic steatohepatitis(NASH),leading to fibrosis and potentially cirrhosis,and it is one of the most common causes of liver disease worldwide.NAFLD is associated with other medical conditions such as metabolic syndrome,obesity,cardiovascular disease and diabetes.NASH can only be diagnosed through liver biopsy,but noninvasive techniques have been developed to identify patients who are most likely to have NASH or fibrosis,reducing the need for liver biopsy and risk to patients.Disease progression varies between individuals and is linked to a number of risk factors.Mechanisms involved in the pathogenesis are associated with diet and lifestyle,influx of free fatty acids to the liver from adipose tissue due to insulin resistance,hepatic oxidative stress,cytokines production,reduced very low-density lipoprotein secretion and intestinal microbiome.Weight loss through improved diet and increased physical activity has been the cornerstone therapy of NAFLD.Recent therapies such as pioglitazone and vitamin E have been shown to be beneficial.Omega 3 polyunsaturated fatty acids and statins may offer additional benefits.Bariatric surgery should be considered in morbidly obese patients.More research is needed to assess the impact of these treatments on a long-term basis.The objective of this article is to briefly review the diagnosis,management and treatment of this disease in order to aid clinicians in managing these patients. 相似文献
84.
85.
Mice are a widely utilized in vivo model for translational salivary gland research but must be used with caution. Specifically, mouse salivary glands are similar in many ways to human salivary glands (i.e., in terms of their anatomy, histology, and physiology) and are both readily available and relatively easy and affordable to maintain. However, there are some significant differences between the two organisms, and by extension, the salivary glands derived from them must be taken into account for translational studies. The current review details pertinent similarities and differences between human and mouse salivary glands and offers practical guidelines for using both for research purposes. 相似文献
86.
Francesco Giorgino MD Jiten Vora MD Peter Fenici MD Anna Solini MD 《Diabetes, obesity & metabolism》2020,22(9):1481-1495
Patients with type 2 diabetes (T2D) are at an increased risk of cardiovascular disease (CVD). Cardiovascular risk in these patients should be considered as a continuum, and comprehensive treatment strategies should aim to target multiple disease risk factors. Large-scale clinical trials of sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown an impact on cardiovascular outcomes, including heart failure hospitalization and cardiovascular death, which appears to be independent of their glucose-lowering efficacy. Reductions in major cardiovascular events appear to be greatest in patients with established CVD, particularly those with prior myocardial infarction, but are independent of heart failure or renal risk. Most large-scale trials of SGLT2 inhibitors predominantly include patients with T2D with pre-existing CVD and high cardiovascular risk at baseline, limiting their applicability to patients typically observed in clinical practice. Real-world evidence from observational studies suggests that there might also be beneficial effects of SGLT2 inhibitors on heart failure hospitalization and all-cause mortality in various cohorts of lower risk patients. The most common adverse events reported in clinical and observational studies are genital infections; however, the overall risk of these events appears to be low and easily managed. Similar safety profiles have been reported for elderly and younger patients. There is still some debate regarding the safety of canagliflozin in patients at high risk of fracture and amputation. Outstanding questions include specific patterns of cardiovascular protection according to baseline risk. 相似文献
87.
RJ Ligthelm M Kaiser J Vora JF Yale 《Journal of the American Geriatrics Society》2012,60(8):1564-1570
Hypoglycemia is a significant problem in elderly adults with diabetes mellitus. Elderly individuals with diabetes mellitus are at greater risk than younger adults for hypoglycemic events. Several factors contribute to this risk, including the high prevalence of comorbidities, polypharmacy, cognitive impairment, and concomitant use of agents that interfere with glucose metabolism. To minimize the risk of hypoglycemia and maximize the benefits of glycemic control, guidelines typically recommend individualizing glycosylated hemoglobin (HbA1c) targets based on life expectancy, functional status, and individual goals. Although many individuals with type 2 diabetes mellitus will ultimately require insulin therapy to achieve and maintain glycemic control, earlier insulin initiation in elderly individuals may be warranted, particularly in those with renal, cardiovascular, or hepatic concerns that could interfere with the use of oral agents. There are few data on the use of insulin-or other glucose-lowering agents-in elderly adults, but limited evidence suggests that the use of insulin, especially insulin analogs, may be appropriate in this population. Insulin analogs offer a better pharmacokinetic profile, greater convenience, and less variable glycemic control than human insulin. Because of the high prevalence of cognitive impairment and other geriatric syndromes in elderly adults, clinicians should perform a comprehensive assessment of patients' ability to administer and monitor insulin therapy and recognize and treat hypoglycemia. 相似文献
88.
Samarasinghe S Steward C Hiwarkar P Saif MA Hough R Webb D Norton A Lawson S Qureshi A Connor P Carey P Skinner R Vora A Pelidis M Gibson B Stewart G Keogh S Goulden N Bonney D Stubbs M Amrolia P Rao K Meyer S Wynn R Veys P 《British journal of haematology》2012,157(3):339-346
We retrospectively analysed the outcome of consecutive children with idiopathic severe aplastic anaemia in the United Kingdom who received immunosuppressive therapy (IST) or matched unrelated donor (MUD) haematopoietic stem cell transplantation (HSCT). The 6-month cumulative response rate following rabbit antithymocyte globulin (ATG)/ciclosporin (IST) was 32·5% (95% CI 19·3-46·6) (n = 43). The 5-year estimated failure-free survival (FFS) following IST was 13·3% (95% confidence interval [CI] 4·0-27·8). In contrast, in 44 successive children who received a 10-antigen (HLA-A, -B, -C, -DRB1, -DQB1) MUD HSCT there was an excellent estimated 5-year FFS of 95·01% (95% CI 81·38-98·74). Forty of these children had failed IST previously. HSCT conditioning was a fludarabine, cyclophosphamide and alemtuzumab (FCC) regimen and did not include radiotherapy. There were no cases of graft failure. Median donor chimerism was 100% (range 88-100%). A conditioning regimen, such as FCC that avoids total body irradiation is ideally suited in children. Our data suggest that MUD HSCT following IST failure offers an excellent outcome and furthermore, if a suitable MUD can be found quickly, MUD HSCT may be a reasonable alternative to IST. 相似文献
89.
Vora AN Bonaca MP Ruff CT Jarolim P Murphy S Croce K Sabatine MS Simon DI Morrow DA 《Journal of thrombosis and thrombolysis》2012,34(2):229-234
Elevated levels of myeloid-related protein (MRP)-8/14 (S100A8/A9) are associated with first cardiovascular events in healthy individuals and worse prognosis in patients with acute coronary syndrome (ACS). The diagnostic utility of MRP-8/14 in patients presenting to the emergency room with symptoms concerning for ACS is uncertain. MRP-8/14 was measured in serial serum and plasma samples in a single center prospective cohort-study of patients presenting to the emergency room with non-traumatic chest pain concerning for ACS. Final diagnosis was adjudicated by an endpoint committee. Of patients with baseline MRP-8/14 results (n = 411), the median concentration in serum was 1.57 μg/ml (25th, 75th: 0.87, 2.68) and in plasma was 0.41 μg/ml (<0.4, 1.15) with only moderate correlation between serum and plasma (ρ = 0.40). A final diagnosis of MI was made in 106 (26%). Peak serum MRP-8/14 was higher in patients presenting with MI (p < 0.001). However, the overall diagnostic performance of MRP-8/14 was poor: sensitivity 28% (95% CI 20-38), specificity 82% (78-86), positive predictive value 36% (26-47), and negative predictive value 77% (72-81). The area under the ROC curve for diagnosis of MI with MRP-8/14 was 0.55 (95% CI 0.51-0.60) compared with 0.95 for cTnI. The diagnostic performance was not improved in early-presenters, patients with negative initial cTnI, or using later MRP-8/14 samples. Patients presenting with MI had elevated levels of serum MRP-8/14 compared to patients with non-cardiac chest pain. However, overall diagnostic performance of MRP-8/14 was poor and neither plasma nor serum MRP-8/14 offered diagnostic utility comparable to cardiac troponin. 相似文献
90.
Mahendra S. Bhavsar Hasmukh B. Vora Lakshman S. Khiria Venugopal H. Giriyappa 《Saudi Journal Of Gastroenterology》2012,18(6):380-383